Theratechnologies issues update on Egrifta SV shortage (THTX:NASDAQ)


FDA headquarters in Washington DC.

JHVEPhoto

Theratechnologies (NASDAQ:THTX) said there will be a shortage of its drug Egrifta SV on the patient level in mid-January due to the voluntary shutdown of a contract manufacturing facility last year.

The Canadian company added that several U.S. pharmacies have reported


Leave a Comment